Published in Immunology on May 01, 1999
The role of cytokines in Guillain-Barré syndrome. J Neurol (2010) 1.00
Molecules involved in the crosstalk between immune- and peripheral nerve Schwann cells. J Clin Immunol (2014) 0.84
Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 9.63
The acute phase response. Immunol Today (1994) 7.53
Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med (1955) 5.81
The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med (1988) 4.31
Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science (1986) 4.25
Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med (1997) 4.06
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 3.98
Multiple actions of interleukin 6 within a cytokine network. Immunol Today (1988) 3.62
IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol (1989) 3.15
Interleukin 6 and its receptor: ten years later. Int Rev Immunol (1998) 2.96
Defective inflammatory response in interleukin 6-deficient mice. J Exp Med (1994) 2.92
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today (1997) 2.37
T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med (1994) 2.31
Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol (1993) 1.82
IL-6: insights into novel biological activities. Clin Immunol Immunopathol (1997) 1.24
Identification of the neuritogen for experimental allergic neuritis. Nature (1979) 1.21
Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol (1994) 1.10
Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain (1995) 1.08
The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine (1993) 1.08
Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J Neuroimmunol (1998) 1.04
Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells. Clin Exp Immunol (1990) 1.02
Comparative analysis of cytokine patterns in immunological, infectious, and oncological neurological disorders. J Neurol Sci (1991) 0.98
Extrapolation of experimental safety data to humans: the interleukin-6 case. Clin Immunol Immunopathol (1997) 0.97
Interleukin 6 inhibits delayed-type hypersensitivity and the development of adjuvant arthritis. Eur J Immunol (1991) 0.95
Nerve lesions induced by macrophage activation. Res Immunol (1993) 0.95
P0 myelin protein produces experimental allergic neuritis in Lewis rats. J Neurol Sci (1987) 0.92
T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol (1990) 0.90
Chronic experimental allergic neuritis. An electrophysiological and histological study in the rabbit. J Neurol Sci (1987) 0.90
Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats. J Neuroimmunol (1998) 0.89
Experimental allergic neuritis (EAN) as a model for the immune-mediated demyelinating neuropathies. Rev Neurol (Paris) (1996) 0.88
Demyelination and axonal degeneration in Lewis rat experimental allergic neuritis depend on the myelin dosage. Lab Invest (1988) 0.87
Intraneural activated T cells cause focal breakdown of the blood-nerve barrier. Brain (1995) 0.87
Synergy between antibody and P2-reactive T cells in experimental allergic neuritis. J Neuroimmunol (1995) 0.86
Circulating tumor necrosis factor-alpha correlates with electrodiagnostic abnormalities in Guillain-Barré syndrome. Ann Neurol (1997) 0.86
New minimum length requirement for a T cell epitope for experimental allergic neuritis. J Neuroimmunol (1990) 0.85
Autoimmunity in the peripheral nervous system. Baillieres Clin Neurol (1996) 0.84
Chronic experimental allergic neuritis in Lewis rats. Neuropathol Appl Neurobiol (1989) 0.84
Induction of severe experimental autoimmune neuritis with a synthetic peptide corresponding to the 53-78 amino acid sequence of the myelin P2 protein. J Neuroimmunol (1990) 0.82
Potential role of autoantibodies in the regulation of cytokine responses during bacterial infections. Infect Immun (1997) 0.80
Suramin inhibits the stimulation of acute phase plasma protein genes by IL-6-type cytokines in rat hepatoma cells. J Immunol (1993) 0.80
Cytokine pattern in the cerebrospinal fluid from patients with GBS and CIDP. J Neurol Sci (1997) 0.80
SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J Struct Biol (1996) 22.89
Lipid rafts reconstituted in model membranes. Biophys J (2001) 9.19
Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost (2001) 6.16
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 4.78
Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A (1998) 4.72
Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res (1995) 4.11
DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature (2000) 4.10
Response to RAG-mediated VDJ cleavage by NBS1 and gamma-H2AX. Science (2000) 3.95
Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med (2001) 3.62
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood (1997) 3.56
A model of protein synthesis based on cryo-electron microscopy of the E. coli ribosome. Nature (1995) 3.56
Effect of mutations in genes affecting homologous recombination on restriction enzyme-mediated and illegitimate recombination in Saccharomyces cerevisiae. Mol Cell Biol (1994) 3.41
Myocardial ischemia and reperfusion: a murine model. Am J Physiol (1995) 3.38
Partitioning of Thy-1, GM1, and cross-linked phospholipid analogs into lipid rafts reconstituted in supported model membrane monolayers. Proc Natl Acad Sci U S A (2001) 3.12
A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci (1999) 2.92
Rocuronium (Org 9426) for caesarean section. Br J Anaesth (1994) 2.86
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet (1999) 2.74
Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol Cell Biol (2000) 2.59
Two-photon fluorescence microscopy of laurdan generalized polarization domains in model and natural membranes. Biophys J (1997) 2.56
Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation (2001) 2.56
Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. J Neurosci (1998) 2.55
An alternative-exon database and its statistical analysis. DNA Cell Biol (2000) 2.51
Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet (2000) 2.49
Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology (2012) 2.45
Three ARS elements contribute to the ura4 replication origin region in the fission yeast, Schizosaccharomyces pombe. EMBO J (1994) 2.38
Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. Diabetologia (2011) 2.37
A common-lines based method for determining orientations for N > 3 particle projections simultaneously. Ultramicroscopy (1996) 2.32
The no-scalpel vasectomy. J Urol (1991) 2.24
Infection and atherosclerosis: emerging mechanistic paradigms. Circulation (1999) 2.23
[Co-morbidity in acutely hospitalised older patients as a risk factor for death in hospital or within 3 months after discharge]. Ned Tijdschr Geneeskd (2007) 2.17
PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release (2001) 2.15
Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol (1992) 2.14
Systematic review of survival after acute mesenteric ischaemia according to disease aetiology. Br J Surg (2004) 2.14
Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost (2004) 2.09
Regulation of nitrogen fixation in Klebsiella pneumoniae: isolation and characterization of strains with nif-lac fusions. J Bacteriol (1981) 2.07
Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol (1998) 2.06
SAGE transcript profiles for p53-dependent growth regulation. Oncogene (1997) 2.06
14-3-3 proteins; bringing new definitions to scaffolding. Oncogene (2001) 2.03
Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. J Thromb Haemost (2015) 2.02
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99
Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain (2001) 1.91
Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein. Proc Natl Acad Sci U S A (1996) 1.86
Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet (1998) 1.80
An interchangeable ELISA for cytomegalovirus antigen and antibody. J Virol Methods (1981) 1.80
Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections. Infect Immun (1983) 1.78
Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci U S A (1992) 1.77
Size dependence of Young's modulus in ZnO nanowires. Phys Rev Lett (2006) 1.74
Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal formation after periadventitial carotid artery injury in genetically hypercholesterolemic mice. Arterioscler Thromb Vasc Biol (2000) 1.73
Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett (1991) 1.73
Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol (2000) 1.71
nompA encodes a PNS-specific, ZP domain protein required to connect mechanosensory dendrites to sensory structures. Neuron (2001) 1.71
Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS (1990) 1.71
Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci U S A (2000) 1.70
Rhinovirus induces MUC5AC in a human infection model and in vitro via NF-κB and EGFR pathways. Eur Respir J (2010) 1.70
Genes that are uniquely stress regulated in salt overly sensitive (sos) mutants. Plant Physiol (2001) 1.69
Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet (1993) 1.68
Developmental quantitative genetics, conditional epigenetic variability and growth in mice. Genetics (1997) 1.66
Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med (1995) 1.65
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med (1994) 1.63
Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax (2004) 1.63
A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem (2000) 1.62
Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. J Med Virol (1989) 1.61
Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer (2009) 1.60
Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol (2001) 1.57
Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J Acquir Immune Defic Syndr (1992) 1.57
Occult polymicrobial endocarditis with Haemophilus parainfluenzae in intravenous drug abusers. Am J Med (1989) 1.57
Identification of a novel, human multilymphoid progenitor in cord blood. Blood (2001) 1.56
Short-term and long-term mortality in very elderly patients admitted to an intensive care unit. Intensive Care Med (2006) 1.55
Intrarenal production of angiotensin II. Semin Nephrol (1997) 1.55
Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis (1990) 1.54
Measurement of the forward-backward charge asymmetry in top-quark pair production. Phys Rev Lett (2008) 1.53
Survival and functional outcome of children requiring endotracheal intubation during therapy for severe traumatic brain injury. Crit Care Med (1997) 1.53
Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol (2000) 1.53
Virus-specific immunoglobulin G subclasses in herpes simplex and varicella-zoster virus infections. J Clin Microbiol (1984) 1.53
Quality of life and metabolic control in patients with diabetes mellitus type 1 treated by continuous subcutaneous insulin infusion or multiple daily insulin injections. Neth J Med (2004) 1.52
Variable Selection for Qualitative Interactions. Stat Methodol (2011) 1.52
Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol (1987) 1.52
Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost (2013) 1.50
Influence of cells and virus multiplicity on the inhibition of herpesviruses with acycloguanosine. Intervirology (1980) 1.50
Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Genes Chromosomes Cancer (1996) 1.49
Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. Infect Immun (1999) 1.48
Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol (2000) 1.48
Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost (1996) 1.47
Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG (2000) 1.47
Measurement of the W boson mass with the D0 detector. Phys Rev Lett (2012) 1.46
Stable three-center hydrogen bonding in a partially rigidified structure. Chemistry (2001) 1.46
Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. Eur Respir J (2006) 1.45
A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. Am J Physiol (1997) 1.44
Quantitative assessment of brain microvascular and tissue oxygenation during cardiac arrest and resuscitation in pigs. Anaesthesia (2013) 1.44
The B cell repertoire in experimental allergic neuritis involves multiple myelin proteins and GM1. J Neurol Sci (1994) 1.43
Evidence for spin-flip scattering and local moments in dilute fluorinated graphene. Phys Rev Lett (2012) 1.43
Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) (2007) 1.43